David Lanzetta

SAGE-718: A First-in-Class N-Methyl-d-Aspartate Receptor Positive Allosteric Modulator for the Potential Treatment of Cognitive Impairment.

M. D. Hill, M. Quirk, F. Salituro, 2022, Journal of medicinal chemistry.

Abstract 3327: Discovery and characterization of the potent, allosteric SHP2 inhibitor GDC-1971 for the treatment of RTK/RAS driven tumors

D. Bergstrom, M. Murcko, D. Shaw, 2022, Cancer Research.